Q1 EPS Estimates for HealthEquity Lowered by Zacks Research

HealthEquity, Inc. (NASDAQ:HQY) – Equities researchers at Zacks Research decreased their Q1 2026 earnings estimates for HealthEquity in a research report issued to clients and investors on Tuesday, April 8th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.63 per share for the quarter, down from their prior forecast of $0.68. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity’s Q2 2026 earnings at $0.72 EPS, Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.85 EPS, FY2026 earnings at $2.90 EPS, Q1 2027 earnings at $0.76 EPS, Q2 2027 earnings at $0.94 EPS, Q3 2027 earnings at $0.93 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.66 EPS.

Several other analysts have also issued reports on HQY. The Goldman Sachs Group cut their target price on shares of HealthEquity from $107.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, March 27th. KeyCorp reduced their price objective on HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Monday, March 24th. Raymond James upgraded HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their target price for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. Wells Fargo & Company upped their price target on HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $112.00 price objective on shares of HealthEquity in a research note on Friday. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, HealthEquity currently has an average rating of “Buy” and a consensus target price of $112.58.

HealthEquity Trading Up 2.8 %

HealthEquity stock opened at $82.20 on Friday. HealthEquity has a 52-week low of $65.01 and a 52-week high of $115.59. The company has a market cap of $7.11 billion, a P/E ratio of 75.41, a P/E/G ratio of 1.60 and a beta of 0.49. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. The business has a 50-day simple moving average of $97.63 and a two-hundred day simple moving average of $96.30.

Insider Activity

In other news, Director Robert W. Selander sold 5,750 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total transaction of $446,487.50. Following the completion of the transaction, the director now directly owns 84,969 shares in the company, valued at approximately $6,597,842.85. This represents a 6.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm’s stock in a transaction on Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the transaction, the executive vice president now directly owns 56,655 shares of the company’s stock, valued at approximately $4,433,820.30. This trade represents a 13.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,381 shares of company stock worth $1,781,432 over the last quarter. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Institutional investors have recently bought and sold shares of the business. Wealthfront Advisers LLC purchased a new position in shares of HealthEquity in the 4th quarter worth approximately $10,304,089,000. T. Rowe Price Investment Management Inc. bought a new stake in HealthEquity in the fourth quarter worth $78,107,000. Norges Bank purchased a new position in HealthEquity during the fourth quarter worth $74,701,000. Raymond James Financial Inc. bought a new position in HealthEquity during the fourth quarter valued at $45,728,000. Finally, Iron Triangle Partners LP purchased a new stake in shares of HealthEquity in the fourth quarter valued at $32,202,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.